Vyriad, Inc. Raises $29.5M in Series B Funding Led by Renowned Genetics Entrepreneur
Vyriad, Inc.Vyriad, Inc., a clinical-stage biotechnology company developing oncolytic virus therapies to treat a wide range of cancers, today announced $29.5M in new funding led by Mr. Harry Stine of Stine Seed Farms, Inc.